Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma

Inclusion Criteria: * Diagnosis of angioimmunoblastic T-cell lymphoma (recurrent or refractory) based on histologic examination. * At least one objective measurable or evaluable disease parameter. * Have failed at least one type of treatment: chemotherapy, auto-transplant, or steroid treatment. Patients may not receive concurrent chemotherapy. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * Adequate renal function as indicated by creatinine \<= 1.5 the upper limit of normal (ULN). * Adequate liver function as indicated by alkaline phosphatase, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) \<= 2x the upper limit of normal. * Total bilirubin \<= 2x the upper limit of normal. * Age 18 or older. Exclusion Criteria: * Prior cyclosporine or Tacrolimus (FK506). * Prior allogeneic transplant. * Evidence of active infection. * Congestive heart failure, kidney failure, liver failure, or other severe co-morbidities. * Evidence of active neurological impairment. * Previous history of hypersensitivity to cyclosporine and/or Cremorphor EL (polyoxyethylated oil). * History of other malignancies (other than cured carcinomas in situ of the cervix or basal cell carcinoma of the skin). * pregnant or breastfeeding women. * Human immunodeficiency virus (HIV) positive.